Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 4/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MC5R | P33032 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723861 | 1.00 | EPOR (0.59) | EPORCPB2MMP2F2MC4R | |
| SCHEMBL29766190 | 0.95 | EPOR (0.54) | EPORCPB2MMP2MC4RMC5R | |
| SCHEMBL19100377 | 0.86 | EPOR (0.49) | EPORCPB2MMP2F2MC4R | |
| SCHEMBL7129391 | 0.86 | EPOR (0.49) | EPORCPB2MMP2F2MC4R | |
| SCHEMBL841611 | 0.86 | ALOX5 (0.50) | EPORGRIK1 | |
| SCHEMBL29104391 | 0.84 | EPOR (0.49) | EPORMMP2MMP9 | |
| SCHEMBL22444191 | 0.84 | KMT2A (0.44) | EPORGRIK1 | |
| SCHEMBL22444192 | 0.84 | KMT2A (0.44) | EPORGRIK1 | |
| SCHEMBL842165 | 0.84 | GRIK1 (0.53) | EPORGRIK1 | |
| Lysine SCHEMBL29207003 | 0.84 | GSR (0.50) | EPORMMP2MC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832110-A1 | ANTIVIRAL PEPTOID COMPOUNDS | Novartis AG (CH) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040759-A1 | ANTIVIRAL PEPTOID COMPOUNDS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | claimed |
| EP-4655313-A2 | PET TRACER FOR DETECTION OF TRANSFORMING GROWTH FACTOR BETA | Providence Health & Services - Oregon (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-120138047-A | Compositions and methods for treating glycogen storage disease type 1a | 比姆医疗股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120138046-A | Compositions and methods for treating alpha 1-antitrypsin deficiency | 比姆医疗股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-114929287-B | Compositions and methods for treating hepatitis B | 比姆医疗股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120082603-A | HLA class II restricted T cell receptor against mutated RAS | 美国卫生和人力服务部 | 2025-06-03 | — | — | CN | disclosed |
| CN-120035667-A | Polycistronic miRNA constructs for immune checkpoint inhibition | 普雷西根公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119978099-A | IL-21 mutant, fusion protein containing same, nucleic acid, recombinant expression vector, host cell, preparation method and application thereof | 华润生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119978098-A | IL-21 mutant, fusion protein containing same, nucleic acid, recombinant expression vector, host cell, preparation method and application thereof | 华润生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119954972-A | Fusion protein containing NHBA and fHbp, immune preparation containing fusion protein and preparation method and application of immune preparation | 苏州聚微生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20150299317-A1 | M971 CHIMERIC ANTIGEN RECEPTORS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2015-10-22 | — | — | US | disclosed |
| CN-104379179-A | Chimeric antigen receptors targeting B-cell maturation antigens | US HEALTH (US) | 2015-02-25 | — | — | CN | disclosed |
| WO-2012054825-A1 | ANTI-MAGE-A3 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| EP-0832110-A1 | ANTIVIRAL PEPTOID COMPOUNDS | Novartis AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
| WO-1996040759-A1 | ANTIVIRAL PEPTOID COMPOUNDS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| EP-0361317-A2 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |